To counteract this effect, strategies aimed at targeting tolerogenic DC-like dysfunction in MM—such as enhancing IL-12 production or inhibiting IL-10—could reflect tactics used against mregDCs in other cancers (103, 104). Here, IL10 is linked to Miyoshi myopathy.